Skip to main content
OpenTrials
Completed

NCT Number: NCT04396405

Investigation of Factors Affecting Cardiorespiratory Fitness in Individuals With Systemic Hypertension

The investigators aim to investigate the factors affecting cardiorespiratory fitness in individuals with systemic hypertension.

Completed

Looking for future studies?

Notify Me

Key information

About this study

Systemic artery hypertension is a condition characterized by persistent high blood pressure (BP) in systemic arteries. Blood pressure is expressed as the rate of systolic BP (SBP) (pressure exerted by the blood on the arterial walls when the heart contracts) and diastolic BP (DBP) (pressure that occurs when the heart is relaxed).

Hypertension is defined as SBP level ≥ 140 mmHg and DBP level ≥ 90 mmHg. Pre-hypertension, defined as the gray area, or increased normal blood pressure, ranges between SBP 130-139 mmHg and DBP 85-89 mmHg. Hypertension is among the most common preventable risk factors for cardiovascular diseases. Although hypertension, which is seen as a silent killer due to the absence of any symptoms in its early stages until a serious medical crisis such as heart attack, stroke or chronic kidney disease, is often asymptomatic, some patients may present with headache, dizziness, visual impairment or fainting spells. There is still too much uncertainty about the pathophysiology of hypertension. Fewer patients (between 2% to 5%) as the cause of increased blood pressure; there is an underlying kidney or adrenal disease. However, one reason is not clearly defined and in the rest condition "essential hypertension" is defined. A number of physiological mechanisms are involved in maintaining normal blood pressure, and irregularities of these mechanisms play a role in the development of essential hypertension. These physiological mechanisms; cardiac output and peripheral resistance, renin-angiotensin-aldosterone system, autonomic nervous system, vasoactive substances, excessive coagulation, insulin sensitivity, genetic factors, diastolic dysfunction and endothelial dysfunction.

Evaluation of exercise capacity and prescribing individualized exercise programs in individuals with increased cardiovascular risk and risk factors is a protective and therapeutic health policy. Hypertensive individuals should be evaluated to evaluate motor and cardiovascular functions and prescribe exercise. Hypertension and the chronic diseases it may cause make it difficult for individuals to perform their daily life activities and may limit the participation of individuals in daily life. The exercise, being one of the most important components involved in the management of hypertension together hypertensive subjects of exercise capacity, activities of daily living (ADL), is considerably less than the studies that assessed in detail the balance parameters and the impact of hypertension as it is made in almost all geriatric population of the studies makes it difficult to demonstrate directly. The aim of our study is to evaluate individuals in terms of all these variables and to determine the factors affecting them, to examine the effect of antihypertensive drugs on daily life activity and exercise capacity, and to examine whether gender differences are observed.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Being 18 or older,
  • Having been diagnosed with primary or secondary hypertension,
  • Volunteering to participate in the study,

Exclusion criteria

  • Has a neurological, cognitive or orthopedic disease that will affect the measurements, Having severe respiratory disease (FEV1 <35%; FVC <50%),
  • Presence of acute infection,
  • Malignancy
  • Dementia,
  • Having hormone replacement therapy,
  • Have had any cardiovascular events in the last 6 months,
  • Body mass index is more than 40 kg / cm2,
  • Ejection fraction less than 50%,
  • Uncontrolled hypertension, diabetes,

Treatment and study plan

Primary outcomes

  1. Exercise Capacity

    Time frame: 1 year

    Exercise capacity assesment with six minute stepper test

  2. Submaximal Exercise Capacity

    Time frame: 1 year

    Exercise capacity assesment with six minute walk test

Secondary outcomes

  1. Quality of Life assesment

    Time frame: 1 year

    Quality of Life assesment with Short form 36

  2. Arterial Stiffness

    Time frame: 1 year

    Pulse wave variability

  3. Medication Adherence

    Time frame: 1 year

    Hill Bone Medication Adherence

  4. Physical Activity

    Time frame: 1 year

    Physical Activity assessed with IPAQ

  5. Ventricular functions ve ventricular structure

    Time frame: 1 year

    Left and right ventricular function assessed with ecocardiography

Sponsors and collaborators

Lead sponsor

Hacettepe University

Other

Registry information

Important dates

Study start
2021
Primary completion
2021
Study completion
2021
First posted
May 20, 2020
Registry last updated
Jul 5, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.